Victrex plc

Victrex is the global pioneer and volume leader in polyether ether ketone (PEEK). PEEK is a semi-crystalline, ultra-high-performance thermoplastic that combines mechanical strength, high-temperature capability, and chemical, wear and fatigue resistance. The company says it holds more than 45% of global PEEK volume, over twice its nearest rival (CMD, 24 Sep 2026). Its vertically integrated, predominantly UK-based chain runs from monomer manufacture in Rotherham to polymerisation at Hillhouse, with additional capacity in Panjin, China. Through Invibio it also serves implantable and non-implantable medical devices. The group sells polymer, film, compounds and selected semi-finished forms into Aerospace & Defence, Automotive, Electronics, Energy & Industrial, Value Added Resellers and Medical. After a profit downturn from FY2023 to FY2025 driven by mix, pricing, FX and a troubled China plant, a new CEO launched a self-help turnaround. The plan targets roughly 50% gross margin and a mid-20s operating margin by FY2031, and resets capital returns around buybacks.

What the company does

Victrex manufactures and sells polyaryletherketone (PAEK) polymers, principally PEEK, under the VICTREX™ brand, plus medical-grade PEEK under the PEEK-OPTIMA™ brand via its Invibio subsidiary. Customers use the polymer to replace metals, fluoropolymers and lower-grade plastics in demanding applications. Typical examples are aircraft brackets and clips, automotive transmission and braking components, semiconductor chemical-mechanical planarisation (CMP) retaining rings, smartphone acoustic film, subsea and oilfield seals and pipes, food-processing equipment, spinal fusion cages, cranio-maxillofacial plates and cardiac pump components.

Company's own description (paraphrased from FY2025 Annual Report and 2026 RNSs)

In its FY2025 reports, Victrex describes itself as an innovative world leader in high-performance polymer solutions. It cites more than 40 years' experience in PEEK and PAEK-based polymers, semi-finished and finished parts, and positions its products as enabling environmental and societal benefits. In September 2026 the corporate website was re-badged around a broader proposition: a leading global materials and engineered-solutions partner that transforms performance in systems the world relies on. The CMD release added "Aerospace and Defence" to the end-market list and dropped the "sustainable materials" framing in favour of mission-critical, certified applications.

Independent characterisation

Victrex is a niche, high-barrier specialty chemicals business whose economics depend heavily on mix. Medical generates about 20% of revenue on under 5% of volume, at gross margins of 75–80%. Sustainable Solutions runs at roughly 34–38% gross margin. The FY2023–FY2025 margin compression (group gross margin from 53.0% to 45.3%) came less from lost volume than from four factors:

1. Rapid growth in low-touch, lower-price VAR and Energy & Industrial tonnage, which pulled ASP down 18% over two years.

2. A structural share shift in US spine from PEEK to porous and expandable titanium cages, plus volume-based procurement (VBP) price resets in Chinese spine.

3. Sterling strength, worth about £8m of PBT headwind in FY2025.

4. Losses at the Panjin plant (about £8m operating loss in FY2025), which never reached its 1,500t nameplate and was impaired by £60.6m in H1 FY2026.

The investment case under the new CEO rests on restoring gross margin through cost and mix discipline, not on volume, which has recovered strongly.

CMD strategy themes (24 Sep 2026; paraphrased)

1. Transform. A decentralised, agile, simplified operating model to build a customer- and performance-focused culture.

2. Grow. Prioritise nearer-term, high-value, high-margin applications where the competitive moat is strongest and Victrex can lead the next round of product development with customers. Combined with underlying end-market growth, this should deliver profitable revenue growth and higher returns on capital.

3. Optimise. Relentless focus on efficiency and cost structure to lift gross and operating margins significantly. Levers include process and operating improvements, digitisation and automation, product rationalisation and supply-chain optimisation.

Market thesis. Global PEEK volumes are expected to grow at about a 5% CAGR over five years. Victrex claims more than 45% volume share, over twice the next competitor. Its differentiation rests on higher load-bearing capacity, faster processing and greater durability, plus vertically integrated, mostly Western manufacturing that offers supply security in regulated markets.

Victrex does not publish price lists; pricing is per-kg and negotiated (group ASP of £68–70/kg in FY2026). Launch years are given only where verified. Grade-level detail reflects company product literature and should be checked against current datasheets.

Mega-programme portfolio

Mega-programmes are defined as programmes with peak-year revenue potential above £50m.

Under the new CEO, mega-programmes are being folded into a more balanced portfolio of short- and long-term opportunities. An up to £10m non-cash portfolio-simplification charge was flagged for H2 FY2026 (Interim Results 2026). Magma and Aerospace Composites continued to hit technical milestones.

All figures in GBP m unless stated. Fiscal years end 30 September. "Underlying" is the company's alternative performance measure (before exceptional items).

Income statement

Sources: FY2021–FY2025 preliminary results; FY2021 ASP and FY2023 gross profit derived (FY2023 from 53.0% reported gross margin); FY2021–FY2023 net income and basic EPS from S&P Global (rounded). FY2021 total includes the 50p special dividend.

Five-year revenue CAGR FY2021–FY2025: −1.1% (derived). Volume CAGR is −1.2%, but this masks a V-shape: volume fell 24% in FY2023 and has since recovered 16% over two years.

Supplementary income-statement metrics (partial disclosure)

n/d = not disclosed in the sources reviewed. FY2025 underlying EBITDA is derived from reported net debt (£24.8m) and net debt/EBITDA of 0.34x (about £73m). FY2022 exceptional items derived as underlying less reported PBT.

EBITDA note. Victrex does not headline EBITDA. Third-party EBITDA (for example, about £86m TTM on TradingView in 2025) differs from the company-implied figure because of definitional differences. Use with caution.

Income-statement commentary

FY2021–FY2022: cyclical high: Post-COVID restocking took volume to a record 4,727t and revenue to a record £341.0m in FY2022. Gross margin slipped from 54.0% to 51.2% as energy and raw-material inflation outpaced price increases, and currency was a drag (underlying PBT +4% reported, +12% at constant currency).

FY2023: destocking shock with price resilience: Volume fell 24% as Electronics, E&I and VARs destocked, but ASP jumped 18% to £85.3/kg on pricing, a richer mix (Medical revenue a record £65.2m) and FX. Gross margin recovered to 53.0%. Underlying PBT fell 16% to £80.0m.

FY2024: Medical destocking and under-absorption: Medical revenue fell sharply (−19% in H1 FY2024) and lower production hurt asset utilisation. Underlying PBT fell 26% to £59.1m. Reported PBT collapsed to £23.4m after £35.7m of exceptionals (Bond 3D associate £21.2m; gears impairment £4.6m; ERP £9.9m).

FY2025: volume up, profit down: Volume rose 12%, led by VARs (+21%) and E&I (+17%), but ASP fell 10% to £70.3/kg. About 80% of the ASP drop came from mix and FX. Medical Spine fell 28%. Headwinds included FX (about £8m), a full-year China plant loss (about £8m) and higher overheads (+14% to £84.2m, including £3.7m of non-cash share incentives restored for retention). Underlying PBT fell 21% to £46.4m, the lowest in more than a decade.

Dividend over-distribution: The 59.56p ordinary dividend has been flat since FY2021. Cover on underlying EPS fell to 0.74x in FY2025 (derived), and dividends were funded partly from the RCF. This set up the CMD rebasing to 30p.

FY2026 in-year data

Sources: Q1 update (Feb 2026), Interim Results 2026, Q3 trading update (7 Jul 2026). Nine-month revenue was £231.6m (+7%) on 3,375t (+10%). Q3 ASP was £68/kg, flat year on year.

FY2026 guidance (9 Sep 2026). Underlying PBT of £45–47m, raised from £42–44m. Total exceptional items expected at £75–85m (Panjin impairment £60.6m, restructuring about £10m, portfolio simplification up to £10m), plus about £3m loss on the Kleiss disposal. A large reported loss for FY2026 is therefore certain.

Balance sheet

Source: S&P Global series, reconciled to FY2024–FY2025 company figures.

Sources: FY2025 Prelims; Interim Results 2026. Working capital derived. Total equity at 1 Oct 2023 was £501.0m. Net debt at 30 Jun 2026 was £43.0m with cash of £27.5m (Q3 update).

Balance-sheet commentary. The group moved from a £96.5m net cash position (FY2021) to net debt in FY2023, driven by roughly £165m of capex over FY2021–FY2023 (China plant, UK asset improvement), the FY2022 special dividend and a 59.56p dividend that earnings no longer covered. The H1 FY2026 impairment cut PPE by about £62m and equity by about £87m. The negative non-controlling interest (−£18.1m) reflects the partner's share of Panjin losses and the impairment. Goodwill and intangibles are small (about £17m), so the book is dominated by tangible manufacturing assets. Inventory (about 244 days of cost of sales in FY2025, derived) remains structurally high against a stated target of about £100m.

Cash flow

Sources: S&P Global series; FY2024–FY2025 match the company cash-flow statement.

Sources: FY2025 Prelims; Interim Results 2026. No buybacks were executed in the period reviewed. Dividends paid were about £52m in FY2023 and about £95m in FY2022 (the latter including the special); both are derived.

Cash-flow commentary. FY2023 free cash flow nearly vanished (£3.2m) as inventory built while volumes collapsed. Inventory unwind and falling capex drove recovery in FY2024–FY2025. Note, however, that FY2024–FY2025 FCF (about £50m a year) roughly equalled the dividend bill (£51.8m), leaving nothing for deleveraging. The CMD capex guide of 5–8% of revenue (previously 8–10%) and the dividend reset to 30p together free up an estimated £35–40m a year for buybacks and special dividends (derived).

Ratios (derived unless stated)

Net debt/underlying EBITDA was 0.65x at H1 FY2026 (company). Company ROIC for FY2026 is expected at a level similar to FY2025's 9%, still below target.

Ratio commentary. Returns are well below Victrex's historic 20%+ ROIC era, reflecting both the profit decline and a capital base inflated by the Panjin build. Liquidity is adequate: committed RCF headroom of £31m at H1, plus a £20m accordion and a new £20m term loan to Oct 2028. Leverage remains modest. The very long cash conversion cycle (above 200 days) is the main working-capital lever, and management targets "strong and improving working capital" within the 90%+ cash-conversion goal.

Management guidance

Broker target moves after the September guidance upgrade imply FY2027 PBT expectations rising toward the mid-£50m range: FY2026 at about £46m plus at least £10m of savings, less energy and FX inflation. This is an analyst inference and should be checked against Victrex's published consensus.

Bull case

1. Self-help is largely in Victrex's control. At least £10m of savings on about £46m PBT is about 22% uplift before any growth. A move from 45% toward 50% gross margin on about £300m revenue adds about £15m of gross profit.

2. Volume and mix are inflecting. Q3 FY2026 revenue rose 18% with ASP flat year on year for the first time in two years. Aerospace and Electronics, both richer-mix markets, led growth, and Medical stabilised.

3. Capital returns are now explicit. At least about £188m over five years (about 23% of market cap) plus a growing dividend, low leverage, and a capex cut to 5–8% that underpins FCF.

Bear case

1. Structural price erosion. VAR and E&I competition, including Chinese capacity, could keep ASP falling and cap gross margin well below 50%. The CMD admits most growth has come from the lowest-margin end markets.

2. The re-rating has run ahead of delivery. At about 920p the shares trade at about 23x FY2026e earnings, above the consensus target (about 808p). Medical recovery is unproven, Panjin needs further investment, and the FY2026 reported result will be a large loss.

3. Execution and leadership risk. There is a new CEO, an interim CFO and a new CCO and MD Medical, plus two board retirements. Energy inflation (only about 40% FY2027 FX hedge cover, energy about 5% of revenue) and sterling strength could absorb much of the savings.

Analyst verdict

Victrex is a fundamentally advantaged franchise that has been run for the past three years as though its advantages were permanent. They were not. Volume leadership in PEEK, a UK-integrated supply chain and a high-margin medical niche remain real assets. The company still sells more PEEK than anyone else, and FY2025 volume of 4,164 tonnes was the third-highest in its history. But growth in that period came mostly from the least differentiated parts of the portfolio. Medical Spine lost ground to titanium. The China plant destroyed rather than created value. And a dividend left untouched by falling earnings forced the group into revolving-credit funding of shareholder distributions. Underlying PBT halved between FY2022 and FY2025.

The 2026 reset under Dr James Routh is credible in its diagnosis and direction. It brings decisive cost action, a portfolio cleanup, a frank impairment of Panjin, the exit from gears, a rebased dividend and a buyback-led return framework anchored to free cash flow. Q3 and Q4 FY2026 trading delivered the first evidence that volume and mix can move together, and guidance was raised. The FY2031 targets of about 50% gross margin and a mid-20s operating margin do not require heroic volume assumptions. They require recovering roughly half the margin lost since FY2023 while holding price discipline in VARs.

The share price has already priced in much of this. At about 920p, roughly 39% above its level a year ago and above the average analyst target, the stock discounts successful delivery of FY2027 savings and some Medical recovery. Our stance is constructive on the business but neutral on the near-term valuation. The decisive tests are FY2027 gross margin, the January 2027 VAR price round and the scale of the first buyback. Evidence of at least 47% gross margin in H1 FY2027 would justify a further re-rating; renewed ASP erosion would not.

*Source notes: All figures are taken from Victrex plc regulatory announcements (FCA National Storage Mechanism and Investegate), the company website and named third-party data providers as cited in each section. "Derived" figures are analyst calculations. "n/d" means not disclosed in the sources reviewed. FY2026 audited results were not available at the time of preparation.

--